Top

Published in:

Open Access 01-12-2017 | Research article

Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate

Authors: Ryuta Arai, Daisuke Takahashi, Masahiro Inoue, Tohru Irie, Tsuyoshi Asano, Takuya Konno, Mohamad Alaa Terkawi, Tomohiro Onodera, Eiji Kondo, Norimasa Iwasaki

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Abstract

Background

Collapse of the femoral head associated with nontraumatic osteonecrosis (NOFH) is one of the most common causes of disability in young adult patients. Excessive bone resorption by osteoclast coincident with the suppression of osteogenesis are believed to be responsible for collapse progression. Alendronate that inhibits bone resorption by inducing osteoclast apoptosis has been traditionally used for treating NOFH; however, several reports documented serious complications by the use of this drug. On the other hand, teriparatide activates osteoblasts leading to an overall increase in bone volume, and is expected to reduce the progression of femoral head collapse in NOFH. Therefore, the present study was undertaken to examine pharmacological effects of teriparatide on collapse progression of NOFH and to compare these effects with alendronate.

Methods

We conducted a retrospective study in our facility for comparing the pharmacological effects of teriparatide and alendronate on 32 NOFH patients diagnosed with osteoporosis. Between 2007 and 2013, patients were treated with daily administration of 20 μg teriparatide (15 patients: 18 hips), or with 35 mg of alendronate once a week (17 patients: 22 hips). The mean period of follow-up was 18.7 months. The progression of collapse was evaluated prior to the administration and later every three months by anteroposterior radiographs. Collapse progression with > 1 mm was defined as advanced collapse, while with < 1 mm was defined as stable radiologic disease. Student’s t-test and the chi-square test was used to do compare the pharmacological effects of the two groups.

Results

Treatment with terparatide had a tendency to reduce the rate of advanced collapse as compared to that with alendronate (p = 0.105). Kaplan-Meier curves related to stable radiologic disease showed that teriparatide-treated patients had better stable states than these treated with alendronate (p = 0.08, log-rank test). Moreover, treatment with teriparatide resulted in a significant reduction in collapse progression as compared to that with alendronate, noted at the end of follow-up period (p = 0.049).

Conclusion

The present study suggests that teriparatide has greater pharmacological effects than alendronate for treating NOFH and preventing the collapse of femoral head.

Trial registration

The registration number in UMIN Clinical Trial Registry is UMIN000017582. The date of registration is May 5, 2015.

Merle D'Aubigné R, Postel M, Mazabraud A, Massias P, Gueguen J, France P. Idiopathic necrosis of the femoral head in adults. J Bone Joint Surg Br. 1965;47:612–33.CrossRefPubMed

Ohzono K, Saito M, Sugano N, Takaoka K, Ono K. The fate of nontraumatic avascular necrosis of the femoral head. A radiologic classification to formulate prognosis. Clin Orthop Relat Res. 1992;277:73–8.

Aaron RK, Lennox D, Bunce GE, Ebert T. The conservative treatment of osteonecrosis of the femoral head. A comparison of core decompression and pulsing electromagnetic fields. Clin Orthop Relat Res. 1989;249:209–18.

Mont MA, Jones LC, Sotereanos DG, Amstutz HC, Hungerford DS. Understanding and treating osteonecrosis of the femoral head. Instr Course Lect. 2000;49:169–85.PubMed

Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am. 1995;77:459–74.CrossRefPubMed

Kenzora JE, Steele RE, Yosipovitch ZH, Glimcher MJ. Experimental osteonecrosis of the femoral head in adult rabbits. Clin Orthop Relat Res. 1978;130:8–46.

Wang C, Wang X, Xu XL, Yuan XL, Gou WL, Wang AY, Guo QY, Peng J, Lu SB. Bone microstructure and regional distribution of osteoblast and osteoclast activity in the osteonecrotic femoral head. PLoS One. 2014;9:e96361.CrossRefPubMedPubMedCentral

Shibayama K. Idiopathic osteonecrosis of the femoral head in the elderly. Kurume Med J. 2000;47:37–43.CrossRefPubMed

Agarwala S, Sule A, Pai BU, Joshi VR. Study of alendronate in avascular necrosis of bone. J Assoc Physicians India. 2001;49:949–50.PubMed

10.

Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res. 2006;443:273–9.CrossRefPubMed

11.

Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br. 2009;91:1013–8.CrossRefPubMed

12.

Chen CH, Chang JK, Lai KA, Hou SM, Chang CH, Wang GJ. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:1572–8.CrossRefPubMed

13.

Niall HD, Sauer RT, Jacobs JW, Keutmann HT, Segre GV, O'Riordan JL, Aurbach GD, Potts Jr JT. The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A. 1974;71:384–8.CrossRefPubMedPubMedCentral

14.

Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138:4607–12.PubMed

15.

Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest. 1993;91:2479–87.CrossRefPubMedPubMedCentral

16.

Mosekilde L, Søgaard CH, Danielsen CC, Tørring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology. 1991;129:421–8.CrossRefPubMed

17.

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932–41.CrossRefPubMed

18.

Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007;65:573–80.CrossRefPubMed

19.

Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009;36:1835–7.CrossRefPubMed

20.

Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2011;33:1366–71.CrossRefPubMed

21.

Dong Y, Li Y, Huang C, Gao K, Weng X. Systemic application of teriparatide for steroid induced osteonecrosis in a rat model. BMC Musculoskelet Disord. 2015;16:163.CrossRefPubMedPubMedCentral

22.

Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci. 2002;7:601–5.CrossRefPubMed

23.

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone. 2010;47:493–502.CrossRefPubMed

24.

Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H. Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. J Bone Miner Metab. 2012;30:326–37.CrossRefPubMed

25.

Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005;23(5):382–8.CrossRefPubMed

26.

Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001;386:173–8.CrossRef

27.

Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005;435:164–70.CrossRef

28.

Wang Y, Yin L, Li Y, Liu P, Cui Q. Preventive effects of puerarin on alcohol-induced osteonecrosis. Clin Orthop Relat Res. 2008;466:1059–67.CrossRefPubMedPubMedCentral

29.

Disch AC, Matziolis G, Perka C. The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J Bone Joint Surg Br. 2005;87:560–4.CrossRefPubMed

30.

Jäger M, Tillmann FP, Thornhill TS, Mahmoudi M, Blondin D, Hetzel GR, et al. Rationale for prostaglandin I2 in bone marrow oedema—from theory to application. Arthritis Res Ther. 2008;10:R120.CrossRefPubMedPubMedCentral

31.

Green J, Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010;37:S3–11.CrossRefPubMed

32.

Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87:2155–9.PubMed

33.

Wong PK, Borromeo GL, Wark JD. Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. Rheumatol Int. 2013;33:2189–98.CrossRefPubMed

34.

Conte Neto N, Spolidorio LC, Andrade CR, Bastos A S, Guimarães M, Marcantonio Jr E. Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol. 2013;94:65–73.CrossRefPubMedPubMedCentral

35.

Bocanegra-Pérez MS, Vicente-Barrero M, Sosa-Henríquez M, Rodríguez-Bocanegra E, Limiñana-Cañal JM, López-Márquez A, et al. Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws. Med Oral Patol Oral Cir Bucal. 2012;17:e948–55.CrossRefPubMedPubMedCentral

36.

Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med. 2014;371:974–6.CrossRefPubMed

37.

Meling T, Nawab A, Harboe K, Fosse L. Atypical femoral fractures in elderly women: a fracture registry-based cohort study. Bone Joint J. 2014;96-B(8):1035–40.CrossRefPubMed

38.

Blum L, Cummings K, Goulet JA, Perdue AM, Mauffrey C, Hake ME. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management. Eur J Orthop Surg Traumatol. 2016;26:371–7.CrossRefPubMed

39.

Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439–46.CrossRefPubMedPubMedCentral

40.

Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846–53.CrossRefPubMed

41.

Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008;90:120–7.CrossRefPubMed

Title: Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate
Authors: Ryuta Arai
Daisuke Takahashi
Masahiro Inoue
Tohru Irie
Tsuyoshi Asano
Takuya Konno
Mohamad Alaa Terkawi
Tomohiro Onodera
Eiji Kondo
Norimasa Iwasaki
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/s12891-016-1379-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

Association of frontal plane knee alignment with foot posture in patients with medial knee osteoarthritis

Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey

Effects of dual-task and walking speed on gait variability in people with chronic ankle instability: a cross-sectional study

Treatment of genu valgum in children by means of temporary hemiepiphysiodesis using eight-plates: short-term findings

Treatment of Charcot Neuroarthropathy and osteomyelitis of the same foot: a retrospective cohort study

Trends in incidence of proximal humerus fractures, surgical procedures and outcomes among elderly hospitalized patients with and without type 2 diabetes in Spain (2001–2013)